SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: August 7, 1996
UNIGENE LABORATORIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------------------------------------
(State or other jurisdiction of incorporation)
0-16005 22-2328609
- ------------------------ ------------------------------------
(Commission File Number) (IRS Employer Identification Number)
110 Little Falls Road
Fairfield, New Jersey 07004
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(201) 882-0860
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events.
On August 7, 1996, the Company extended the expiration date of
its Class B Warrants from August 11, 1996 to September 10, 1996.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
28 Press Release dated August 7, 1996 regarding
extension of Class B Warrants.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
UNIGENE LABORATORIES, INC.
By S/RONALD S. LEVY
Ronald S. Levy, Vice President
Date: August 13, 1996
FOR IMMEDIATE RELEASE Contact: William Steinhauer, Controller
Unigene Laboratories, Inc.
(201) 882-0860
UNIGENE LABORATORIES EXTENDS
CLASS B WARRANT EXPIRATION DATE
Fairfield, NJ, August 7, 1996 -- Unigene Laboratories, Inc. (Nasdaq:UGNE) today
announced that it is extending the expiration date of its Class B Warrants
(Nasdaq:UGNEZ) by 30 days to September 10, 1996. Each Class B Warrant is
currently exercisable at $3.504 for 1.4269 shares of Common Stock.
Unigene Laboratories, Inc. has developed a proprietary amidation process capable
of producing peptide hormones for the treatment of a variety of diseases and
disorders including osteoporosis, hypertension and arthritis.
